Technological development of cylindrical and flat shaped high energy density capacitors

Cylindrical wound metallized film capacitors rated 2 micron F 500 VDC that had an energy density greater than 0.3 J/g, and flat flexible metallized film capacitors rated at 2 micron F 500 VDC that had an energy density greater than 0.1 J/g were developed. Polysulfone, polycarbonate, and polyvinylidene fluoride (PVF2) were investigated as dielectrics for the cylindrical units. PVF2 in 6.0 micron m thickness was employed in the final components of both types. Capacitance and dissipation factor measurements were made over the range 25 C to 100 C, and 10 Hz to 10 kHz. No pre-life-test burning was performed, and six of ten cylindrical units survived a 2500 hour AC plus DC lift test. Three of the four failures were infant mortality. All but two of the flat components survived 400 hours. Finished energy densities were 0.104 J/g at 500 V and 0.200 J/g at 700 V, the energy density being limited by the availability of thin PVF2 films

Experimental evaluation of three leak detection and location concepts for space stations

Three leak (or precursor damage modes) detection and location concepts for space station overboard leakage were evaluated experimentally. The techniques are: (1) static and dynamic seal leak detector sensing of moisture or all gases in space cabin atmosphere, (2) active ultrasonic Lamb-wave detection of flaws or cracks in cabin wall, and (3) impact gage detection of stress waves induced in cabin pressure wall by meteoroid or orbital impact. The experimental results obtained in the program demonstrated that all three leak detection and location concepts are feasible. With further development, the methods can be integrated into an effective damage control system for advanced manned earth-orbital systems

Complexity for extended dynamical systems

We consider dynamical systems for which the spatial extension plays an important role. For these systems, the notions of attractor, epsilon-entropy and topological entropy per unit time and volume have been introduced previously. In this paper we use the notion of Kolmogorov complexity to introduce, for extended dynamical systems, a notion of complexity per unit time and volume which plays the same role as the metric entropy for classical dynamical systems. We introduce this notion as an almost sure limit on orbits of the system. Moreover we prove a kind of variational principle for this complexity.Comment: 29 page

Global attractors for Cahn-Hilliard equations with non constant mobility

We address, in a three-dimensional spatial setting, both the viscous and the standard Cahn-Hilliard equation with a nonconstant mobility coefficient. As it was shown in J.W. Barrett and J.W. Blowey, Math. Comp., 68 (1999), 487-517, one cannot expect uniqueness of the solution to the related initial and boundary value problems. Nevertheless, referring to J. Ball's theory of generalized semiflows, we are able to prove existence of compact quasi-invariant global attractors for the associated dynamical processes settled in the natural "finite energy" space. A key point in the proof is a careful use of the energy equality, combined with the derivation of a "local compactness" estimate for systems with supercritical nonlinearities, which may have an independent interest. Under growth restrictions on the configuration potential, we also show existence of a compact global attractor for the semiflow generated by the (weaker) solutions to the nonviscous equation characterized by a "finite entropy" condition

Global attractors for strongly damped wave equations with displacement dependent damping and nonlinear source term of critical exponent

In this paper the long time behaviour of the solutions of 3-D strongly damped wave equation is studied. It is shown that the semigroup generated by this equation possesses a global attractor in H_{0}^{1}(\Omega)\times L_{2}(\Omega) and then it is proved that this global attractor is a bounded subset of H^{2}(\Omega)\times H^{2}(\Omega) and also a global attractor in H^{2}(\Omega)\cap H_{0}^{1}(\Omega)\times H_{0}^{1}(\Omega)

Study of damage control systems for space station

Damage control systems for detecting and locating overboard and onboard leak and damage modes on space station

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)